Your browser is no longer supported. Please, upgrade your browser.
Settings
GILD Gilead Sciences Inc. daily Stock Chart
GILD [NASD]
Gilead Sciences Inc.
IndexS&P 500 P/E7.34 EPS (ttm)11.69 Insider Own0.50% Shs Outstand1.32B Perf Week3.85%
Market Cap113.61B Forward P/E6.93 EPS next Y12.38 Insider Trans-15.74% Shs Float1.32B Perf Month-11.53%
Income17.34B PEG5.86 EPS next Q2.99 Inst Own81.90% Short Float2.12% Perf Quarter-1.16%
Sales32.84B P/S3.46 EPS this Y62.00% Inst Trans-6.02% Short Ratio2.61 Perf Half Y-19.65%
Book/sh9.69 P/B8.86 EPS next Y2.62% ROA36.20% Target Price111.29 Perf Year-22.27%
Cash/sh6.28 P/C13.66 EPS next 5Y1.25% ROE104.50% 52W Range81.28 - 121.77 Perf YTD-14.78%
Dividend1.88 P/FCF7.14 EPS past 5Y48.30% ROI45.90% 52W High-29.52% Beta1.12
Dividend %2.19% Quick Ratio1.60 Sales past 5Y32.60% Gross Margin86.90% 52W Low5.59% ATR1.91
Employees8000 Current Ratio1.80 Sales Q/Q2.60% Oper. Margin64.80% RSI (14)46.12 Volatility1.92% 2.16%
OptionableYes Debt/Eq1.70 EPS Q/Q-13.70% Profit Margin52.20% Rel Volume0.57 Prev Close85.29
ShortableYes LT Debt/Eq1.57 EarningsApr 28 AMC Payout14.50% Avg Volume10.75M Price85.82
Recom2.10 SMA201.14% SMA50-6.24% SMA200-11.73% Volume6,123,190 Change0.62%
Apr-29-16Reiterated UBS Buy $130 → $118
Apr-29-16Downgrade Maxim Group Buy → Hold
Mar-16-16Reiterated Leerink Partners Outperform $130 → $127
Feb-25-16Initiated Citigroup Buy $110
Feb-12-16Reiterated Maxim Group Buy $137 → $115
Feb-03-16Reiterated RBC Capital Mkts Outperform $130 → $120
Feb-03-16Reiterated Piper Jaffray Overweight $134 → $114
Feb-03-16Reiterated Oppenheimer Outperform $124 → $120
Feb-03-16Reiterated Barclays Overweight $130 → $115
Feb-03-16Initiated Standpoint Research Buy $110
Jan-20-16Initiated Credit Suisse Outperform $125
Jan-15-16Upgrade BofA/Merrill Underperform → Neutral $107
Oct-28-15Reiterated Maxim Group Buy $129 → $137
Oct-20-15Reiterated Oppenheimer Outperform $120 → $124
Oct-02-15Downgrade Morgan Stanley Overweight → Equal-Weight
Sep-09-15Initiated Jefferies Hold
Jul-29-15Reiterated RBC Capital Mkts Outperform $120 → $130
Jul-29-15Reiterated Piper Jaffray Overweight $131 → $134
Jul-29-15Reiterated Oppenheimer Outperform $86 → $120
Jul-29-15Reiterated Needham Buy $120 → $125
May-27-16 05:03PM  Gilead Subpoenaed as Feds Probe Charity Connections
04:20PM  3 Retirement Stocks to Buy in June at Motley Fool
02:59PM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violations by Certain Officers and Directors of Gilead Sciences Inc. Business Wire
11:42AM  3 Stand-Out Health Care Stocks for Dividends and Growth
11:35AM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences Inc. - GILD PR Newswire
11:07AM  Inside Bristol-Myers Squibbs Virology Segment
10:57AM  Gilead Gets European CHMP's Positive Opinion For Epclusa For All Genotypes of Chronic Hepatitis C Treatment
10:29AM  Gilead Sciences: Why HIV Sales Could Save the Day at Barrons.com
08:07AM  EU regulators back approval of Gilead's new hep C drug Reuters
07:26AM  EU regulators recommend approving Gilead's new hepatitis C drug Reuters
07:25AM  European CHMP Adopts Positive Opinion for Gileads Epclusa┬« (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C Business Wire
05:00AM  Gilead Subpoenaed as Feds Probe Drugmaker-Charity Connections at Bloomberg
May-26-16 02:31PM  Gilead and Celgene Among Biotechnology Stocks to Buy
01:58PM  Investors Eager for Gilead to Make Big Moves
01:40PM  Biotech Giant Gilead Sciences Goes on Sale at Kiplinger
01:38PM  Could Rally Cool Off Ahead Of Friday's GDP Data and Yellen Speech?
10:34AM  Please Gilead, Celgene and Amgen. Don't Buy Medivation. at Barrons.com
09:04AM  Better Buy: Gilead Sciences Inc. vs. Johnson & Johnson at Motley Fool
08:10AM  7 Companies in the Fight to Defeat the Zika Virus at 24/7 Wall St.
06:00AM  'Mad Money' Lightning Round: I'm Buying Buffett's Berkshire Hathaway
12:13AM  [$$] Gilead: What the Stock Needs to Bounce Back at The Wall Street Journal
May-25-16 06:42PM  3 Stocks the Market Loves to Hate, but You Should Love at Motley Fool
05:43PM  [$$] Gilead a Buy Amid a Big Management Shake-Up at Barrons.com
05:16PM  [$$] Gilead: What the Stock Needs to Bounce Back at The Wall Street Journal
04:59PM  Medivation: Three Biotech Giants Enter. Which One Leaves? at Barrons.com
04:08PM  Sanofi Moves To Replace Medivations Board As New Buyers Rumored
03:02PM  Gilead Sciences: Goodbye Buybacks, Hello M&A? at Barrons.com
12:16PM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers
11:02AM  Gilead (GILD) Shares Spike After Executive Board Appointment
10:44AM  Gilead Sciences: Executive Changes are 'Negative Signals' But at Barrons.com
08:23AM  Celgene, Gilead Said to Join Suitors Mulling Medivation Bids at Bloomberg
08:20AM  Short Sellers Grow More Selective on Major Biotechs at 24/7 Wall St.
08:01AM  Billionaires Are Bailing on Gilead Sciences -- Should You, Too? at Motley Fool
May-24-16 05:30PM  [$$] Gilead Names New Operating Chief at The Wall Street Journal
04:43PM  Gilead Sciences names Kevin Young COO at MarketWatch
04:30PM  Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy Business Wire
02:21PM  The stocks fighting Zika
10:54AM  What the Sharp Dropoff in Buybacks Says About the Market
May-23-16 12:25PM  Biotech: The Next Pricing Controversy? at Barrons.com
08:40AM  Your 2016 Guide to Investing in Gilead Sciences Stock at Motley Fool
05:57AM  [$$] Gilead Sciences Spinning Its Wheels at Barrons.com
May-21-16 12:07PM  Billionaire George Soros' Fund Bought These Stocks: Should You? at Motley Fool
May-20-16 05:00PM  Gilead Sciences to Present at the UBS Global Healthcare Conference on Monday, May 23 Business Wire
04:41PM  One Reason Why Gilead (GILD) Stock Closed Up Today
03:41PM  Gilead Sciences: It's More Than Hepatitis CBut Not Enough More For Now at Barrons.com
12:36PM  J&J is Worth as Much as Gilead, Biogen, Mylan, Celgene and Teva Combined. It's Time to Sell. at Barrons.com
11:08AM  Gilead Sciences: Where Do We Go From Here? at Barrons.com
10:04AM  Understanding Gilead Sciences HIV Expansion across Geographies
09:20AM  These 4 Value Stocks Are Collectively Generating $114 Billion in Free Cash Flow a Year at Motley Fool
08:36AM  Four reasons for investors to buy biotechnology stocks now at MarketWatch
May-19-16 04:04PM  The 52-Week Low Club for Thursday at 24/7 Wall St.
12:16PM  XBI Large-Caps: Why Is BioMarin Inching Higher?
10:10AM  A $3B Fund Manager Shares His List Of Best US Companies To Invest at Forbes
10:10AM  A $3B Fund Manager Shares His List Of Best U.S. Companies To Invest at Forbes
09:55AM  Should You Buy These 6 Oversold Stocks? The Charts Say No
May-18-16 06:05PM  Gilead Sciences Big Growth Opportunity for 2016 Is HCV
04:39PM  Gilead Sciences, Inc. -- Moody's affirms Gilead's A3 rating; outlook revised to stable at Moody's
01:05PM  Inside Gilead Sciences Involvement in TAF Therapies
11:09AM  Gilead Should Turn to Acquisitions to Drive Future Growth
08:30AM  This 10-Time Winner Is Offering A New Opportunity
May-17-16 07:00PM  Cramer: What the heck happened to this stock? I can't figure it out at CNBC
03:02PM  5 Top Biotech Stocks to Buy on Sale at Motley Fool
02:37PM  GILEAD SCIENCES INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote of
10:03AM  Gilead Sciences: Is There Upside in Hepatitis C? at Barrons.com
May-16-16 05:05PM  Inside Alexions Metabolic Drugs Kanuma and Strensiq Market Realist
02:23PM  6 Oversold Stocks That Aren't as Ugly as They Look at TheStreet
01:10PM  Big Biotech: What's the Worst Case Scenario? at Barrons.com
01:00PM  Mariner Investments Top Healthcare Picks at Insider Monkey
11:20AM  Biotech Giant Gilead Sciences Goes on Sale at Kiplinger
May-15-16 08:02AM  Warren Buffett's Best Nugget of Wisdom Is Somewhat Strange at Motley Fool
07:42AM  5 Great Stocks on Sale Now at Motley Fool
05:42AM  Gabalex Capital Managements Top Stock Picks for Q2 at Insider Monkey
May-14-16 03:30PM  Vermont to require drug makers to explain price increases AP
May-13-16 05:42PM  5 Surprising Comments in Merck's Quarterly Conference Call at Motley Fool
07:42AM  3 Value Stocks Near 52-Week Lows Worth Buying at Motley Fool
May-12-16 01:23PM  Is Gilead on the Road to Recovery? at TheStreet
01:04PM  GILEAD SCIENCES INC Financials EDGAR Online Financials
12:20PM  Stocks: Healthcare's More Than Just Biotech at Barrons.com
11:16AM  Why Now's the Time to Buy Shares of Gilead Sciences at TheStreet
09:07AM  Behind Gilead Sciences Pricing Pressures for HCV Drugs in the US Market Realist
08:00AM  Pharma's Game of (Hep C) Thrones at Bloomberg
03:07AM  Inside Gilead Sciences Active Involvement in Drugs for NASH Market Realist
May-11-16 01:17PM  Understanding Amgens Analyst Recommendations in 2016 Market Realist
09:30AM  Winton Capital Reduces Size of Several Top Holdings Entering Q2 at Insider Monkey
09:09AM  The Story behind Medivations Rising Collaboration Revenue Market Realist
08:15AM  Short Sellers Run for Cover From Major Biotechs at 24/7 Wall St.
May-10-16 05:11PM  India Patent Office approves Gilead's hepatitis C drug patent Reuters
04:21PM  Do Sluggish Sales of Harvoni Make Gilead Sciences a "Sell"? at Motley Fool
01:33PM  Pro: Impossible to successfully time the market CNBC
09:08AM  Gilead Sciences Thinks Its Own Stock Is a Biotech Bargain at Motley Fool
May-09-16 09:19PM  Breaking Down XLV: 3 Components That Are Most Attractive at Investopedia
05:00PM  Gilead Sciences to Present at the Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 10 Business Wire
03:23PM  Wall Street struggles for gains as crude falls Yahoo Finance
10:18AM  Gilead Sciences: A Black Box of Uncertainty? at Barrons.com
10:08AM  Merck's Mixed Q1 Results Are Marred By 1 Disappointing Drug Debut at Motley Fool
May-08-16 12:17PM  3 Growth Dividend Stocks to Buy in May at Motley Fool
May-07-16 04:00PM  Biotech Is Ripe for M&A: Analysts at TheStreet
08:00AM  3 Top Stocks for Low-Risk Investors at Motley Fool
12:43AM  Gilead Stock: Capital Structure Analysis (GILD) at Investopedia
May-06-16 04:51PM  GILEAD SCIENCES INC Files SEC form 10-Q, Quarterly Report EDGAR Online
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in areas of unmet medical needs in North America, South America, Europe, and the Asia-Pacific. The company's products include Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, Tybost, and Vitekta for the treatment of human immunodeficiency virus (HIV) infection in adults; and Harvoni, Sovaldi, Viread, and Hepsera products for the treatment of liver diseases. It also offers Zydelig, a PI3K delta inhibitor, in combination with rituximab, for the treatment of certain blood cancers; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, the company provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular age-related macular degeneration. Further, it has product candidates in various stages of development for the treatment of HIV/AIDS and liver diseases, such as hepatitis B virus and hepatitis C virus; inflammation/oncology; serious cardiovascular; and respiratory conditions, as well as diabetic nephropathy and ebola. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaboration agreements with Bristol-Myers Squibb Company, Janssen R&D Ireland, Japan Tobacco Inc., and Galapagos NV. The company was founded in 1987 and is headquartered in Foster City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MARTIN JOHN CExecutive ChairmanMay 02Option Exercise16.40100,0001,639,5004,119,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Option Exercise16.40112,0001,836,2401,170,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Option Exercise39.132,00078,25563,122May 04 04:23 PM
MARTIN JOHN CExecutive ChairmanMay 02Sale87.82100,0008,781,6944,019,727May 04 02:44 PM
MILLIGAN JOHN FPresident and CEOMay 02Sale87.71112,0009,823,9541,058,963May 04 02:49 PM
Carter Paul RutherfordEVP Commercial OpsMay 02Sale88.722,000177,44861,122May 04 04:23 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Option Exercise26.9935,874968,239177,964Apr 21 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsApr 19Sale100.0140,0004,000,574137,964Apr 21 01:28 PM
MILLIGAN JOHN FPresident and CEOApr 04Option Exercise16.40112,0001,836,2401,170,963Apr 05 07:30 PM
MILLIGAN JOHN FPresident and CEOApr 04Sale94.59112,00010,593,9041,058,963Apr 05 07:30 PM
MARTIN JOHN CExecutive ChairmanApr 01Option Exercise16.40100,0001,639,5004,119,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Option Exercise24.912,00049,81063,122Apr 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsApr 01Sale91.235,000456,158142,090Apr 05 07:45 PM
MARTIN JOHN CExecutive ChairmanApr 01Sale93.24100,0009,323,5074,019,727Apr 05 07:49 PM
Carter Paul RutherfordEVP Commercial OpsApr 01Sale91.342,000182,68061,122Apr 05 06:36 PM
Alton Gregg HEVP, Corp & Med AffairsMar 14Sale90.005,000450,000147,090Mar 15 07:31 PM
MARTIN JOHN CChairman and CEOMar 01Option Exercise16.40100,0001,639,5004,119,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Option Exercise16.40112,0001,836,2401,170,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Option Exercise24.912,00049,81063,122Mar 03 03:10 PM
MARTIN JOHN CChairman and CEOMar 01Sale88.58100,0008,857,8544,019,727Mar 03 02:47 PM
MILLIGAN JOHN FPresident, COO and DirectorMar 01Sale87.79112,0009,832,9951,058,963Mar 03 02:54 PM
Carter Paul RutherfordEVP Commercial OpsMar 01Sale87.902,000175,80061,122Mar 03 03:10 PM
Washington Robin LEVP, CFOFeb 16Sale90.726,250567,00084,688Feb 18 07:59 PM
MARTIN JOHN CChairman and CEOFeb 01Option Exercise16.40100,0001,639,5004,048,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Option Exercise39.142,00078,27150,783Feb 03 05:42 PM
Carter Paul RutherfordEVP Commercial OpsFeb 01Sale82.322,000164,64048,783Feb 03 05:42 PM
MARTIN JOHN CChairman and CEOFeb 01Sale83.42100,0008,342,4753,948,066Feb 03 05:43 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Option Exercise25.762,00051,52650,783Jan 06 05:08 PM
MARTIN JOHN CChairman and CEOJan 04Option Exercise16.40100,0001,639,5004,048,066Jan 06 05:21 PM
MARTIN JOHN CChairman and CEOJan 04Sale97.68100,0009,767,7083,948,066Jan 06 05:21 PM
Carter Paul RutherfordEVP Commercial OpsJan 04Sale99.202,000198,40048,783Jan 06 05:08 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Option Exercise21.9970,0001,539,562197,936Dec 17 03:40 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSODec 15Sale102.4170,0007,168,741127,936Dec 17 03:40 PM
MILLIGAN JOHN FPresident and COODec 07Option Exercise14.50100,0001,450,2501,129,108Dec 09 02:14 PM
MILLIGAN JOHN FPresident and COODec 07Sale103.18100,00010,317,9771,029,108Dec 09 02:14 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Option Exercise24.3010,000242,950141,422Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Option Exercise26.992,00053,98050,783Dec 03 01:56 PM
MARTIN JOHN CChairman and CEODec 01Option Exercise14.50150,0002,175,3754,098,066Dec 03 01:57 PM
MARTIN JOHN CChairman and CEODec 01Sale105.82150,00015,873,4673,948,066Dec 03 01:57 PM
Carter Paul RutherfordEVP Commercial OpsDec 01Sale106.382,000212,76048,783Dec 03 01:56 PM
Alton Gregg HEVP, Corp & Med AffairsDec 01Sale106.0112,0001,272,159129,422Dec 03 01:57 PM
Cogan John FrancisDirectorNov 24Option Exercise20.7115,000310,57559,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 24Sale106.4816917,99530,719Nov 25 02:22 PM
Cogan John FrancisDirectorNov 24Sale105.9515,0001,589,19044,309Nov 25 02:21 PM
Whitley Richard JamesDirectorNov 23Sale107.182,863306,84530,888Nov 25 02:22 PM
Whitley Richard JamesDirectorNov 20Sale106.995,514589,91733,751Nov 25 02:22 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Option Exercise23.7670,0001,662,850235,168Nov 18 12:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSONov 16Sale102.6570,0007,185,419165,168Nov 18 12:32 PM
MILLIGAN JOHN FPresident and COONov 09Option Exercise14.50100,0001,450,2501,129,108Nov 12 01:01 PM
MILLIGAN JOHN FPresident and COONov 09Sale107.66100,00010,765,6441,029,108Nov 12 01:01 PM
Washington Robin LEVP, CFONov 05Option Exercise0.006,000033,724Nov 09 05:41 PM
MARTIN JOHN CChairman and CEONov 02Option Exercise14.50150,0002,175,3754,098,066Nov 04 01:23 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Option Exercise24.3010,000242,950143,422Nov 04 02:41 PM
MARTIN JOHN CChairman and CEONov 02Sale109.42150,00016,413,0263,948,066Nov 04 01:23 PM
Carter Paul RutherfordEVP Commercial OpsNov 02Sale108.362,000216,71248,783Nov 04 04:27 PM
Washington Robin LEVP, CFONov 02Sale109.466,250684,15088,046Nov 04 04:21 PM
Alton Gregg HEVP, Corp & Med AffairsNov 02Sale109.3812,0001,312,507131,422Nov 04 02:41 PM
Cogan John FrancisDirectorOct 27Option Exercise20.7115,000310,57559,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 27Sale110.0015,0001,650,00044,309Oct 28 08:13 PM
Cogan John FrancisDirectorOct 26Option Exercise20.7115,000310,57559,309Oct 27 03:09 PM
Cogan John FrancisDirectorOct 26Sale110.0015,0001,650,00044,309Oct 27 03:09 PM
Carter Paul RutherfordEVP Commercial OpsOct 26Sale110.061,500165,09248,783Oct 28 02:51 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Option Exercise23.6070,0001,652,248235,168Oct 16 05:32 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOOct 15Sale100.0570,0007,003,220165,168Oct 16 05:32 PM
MILLIGAN JOHN FPresident and COOOct 07Option Exercise14.50100,0001,450,2501,129,108Oct 08 02:06 PM
MILLIGAN JOHN FPresident and COOOct 07Sale99.22100,0009,921,5241,029,108Oct 08 02:06 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Option Exercise24.305,000121,475138,422Oct 07 01:22 PM
Alton Gregg HEVP, Corp & Med AffairsOct 05Sale100.005,000500,000133,422Oct 07 01:22 PM
MARTIN JOHN CChairman and CEOOct 01Option Exercise14.50150,0002,175,3754,098,066Oct 05 01:28 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Option Exercise24.305,000121,475140,422Oct 05 02:13 PM
Alton Gregg HEVP, Corp & Med AffairsOct 01Sale97.287,000680,930133,422Oct 05 02:13 PM
MARTIN JOHN CChairman and CEOOct 01Sale97.48150,00014,622,2893,948,066Oct 05 01:28 PM
Carter Paul RutherfordEVP Commercial OpsOct 01Sale98.592,000197,18048,783Oct 05 04:26 PM
Cogan John FrancisDirectorSep 15Option Exercise20.7115,000310,57559,309Sep 17 03:54 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Option Exercise23.6070,0001,652,000235,168Sep 17 04:26 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Option Exercise24.305,000121,475140,422Sep 17 03:55 PM
Alton Gregg HEVP, Corp & Med AffairsSep 15Sale110.005,000550,000135,422Sep 17 03:55 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOSep 15Sale110.7070,0007,749,195165,168Sep 17 04:26 PM
Cogan John FrancisDirectorSep 15Sale110.0015,0001,650,00044,309Sep 17 03:54 PM
MILLIGAN JOHN FPresident and COOSep 08Option Exercise14.50100,0001,450,2501,129,108Sep 10 02:57 PM
MILLIGAN JOHN FPresident and COOSep 08Sale103.39100,00010,338,7301,029,108Sep 10 02:57 PM
Washington Robin LEVP, CFOSep 02Sale102.206,250638,77894,296Sep 03 03:07 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Option Exercise24.2210,000242,208147,422Sep 03 03:06 PM
Alton Gregg HEVP, Corp & Med AffairsSep 01Sale102.7512,0001,233,008135,422Sep 03 03:06 PM
WILSON GAYLE EDirectorAug 28Option Exercise20.7180,0001,656,400122,769Aug 31 06:17 PM
WILSON GAYLE EDirectorAug 28Sale106.9621,0002,246,160101,769Aug 31 06:17 PM
MARTIN JOHN CChairman and CEOAug 25Sale105.17133,21314,009,8720Aug 26 05:51 PM
Cogan John FrancisDirectorAug 03Option Exercise20.7115,000310,57559,309Aug 04 05:01 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Option Exercise23.7615,000356,325154,422Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Option Exercise14.50150,0002,175,3754,364,492Aug 04 05:07 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Option Exercise26.995,000134,95053,783Aug 04 05:08 PM
Carter Paul RutherfordEVP Commercial OpsAug 03Sale119.185,000595,92048,783Aug 04 05:08 PM
MARTIN JOHN CChairman and CEOAug 03Sale119.18150,00017,876,6194,214,492Aug 04 05:07 PM
Alton Gregg HEVP, Corp & Med AffairsAug 03Sale119.1117,0002,024,870137,422Aug 04 05:08 PM
Cogan John FrancisDirectorAug 03Sale120.0015,0001,800,00044,309Aug 04 05:01 PM
Carter Paul RutherfordEVP Commercial OpsJul 31Option Exercise0.002,500050,132Aug 04 05:00 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Option Exercise21.5870,0001,510,250235,168Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 15Sale118.2066,2617,832,152168,907Jul 17 03:57 PM
BISCHOFBERGER NORBERT WEVP, R&D and CSOJul 07Sale119.393,739446,400165,168Jul 17 03:57 PM
Carter Paul RutherfordEVP Commercial OpsJul 01Option Exercise26.993,00080,97050,632Jul 06 04:00 PM